Dublin, Jan. 24, 2022 (GLOBE NEWSWIRE) -- The "Fabry Disease- Market Insight, Epidemiology and Market Forecast -2030" report has been added to ResearchAndMarkets.com's offering.
The report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the market trends of Fabry Disease in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
Scope of the Report
- The report covers the descriptive overview of Fabry Disease, explaining its causes, signs and symptoms, pathophysiology, and currently available therapies.
- Comprehensive insight has been provided into the Fabry Disease epidemiology and treatment in the 7MM.
- Additionally, an all-inclusive account of both the current and emerging therapies for Fabry Disease is provided, along with the assessment of new therapies, which will impact the current treatment landscape.
- A detailed review of the Fabry Disease market, historical and forecasted, is included in the report, covering drug outreach in the 7MM.
- The report provides an edge while developing business strategies by understanding trends shaping and driving the global Fabry Disease market.
The Fabry Disease market report provides current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted Fabry Disease market Size from 2018 to 2030, segmented by seven major markets. The report also covers the current Fabry Disease treatment practice/algorithm, SWOT analysis, and unmet medical needs to curate the best opportunities and assess the underlying market potential.
In the coming years, the Fabry Disease market is set to change due to the rising awareness of the disease and incremental healthcare spending across the world, which would expand the size of the market to enable the drug manufacturers to penetrate more into the market. The companies and academics are working to assess challenges and seek opportunities that could influence Fabry Disease R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition. Major players are involved in developing therapies for Fabry Disease. The launch of emerging therapies will significantly impact the Fabry Disease market.
A better understanding of disease pathogenesis will also contribute to developing novel therapeutics for Fabry Disease. This in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competitor, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.
Report Insights
- Patient Population
- Therapeutic Approaches
- Fabry Disease Pipeline Analysis
- Fabry Disease Market Size and Trends
- Market Opportunities
- Impact of upcoming Therapies
Report Assessment
- Current Treatment Practices
- Unmet Needs
- Pipeline Product Profiles
- Market Attractiveness
- SWOT Analysis
- Key Questions
Market Insights:
- What was the Fabry Disease Market share (%) distribution in 2018, and how would it look like in 2030?
- What would be the Fabry Disease total market Size and market Size by therapies across the 7MM during the forecast period (2018 - 2030)?
- What are the key findings pertaining to the market across 7MM, and which country will have the largest Fabry Disease market Size during the forecast period (2018 - 2030)?
- At what CAGR is the Fabry Disease market expected to grow in the 7MM forecast period (2018 - 2030)?
- What would be the Fabry Disease market outlook across the 7MM during the forecast period (2018 - 2030)?
- What would be the Fabry Disease market growth till 2030, and what will be the resultant market Size in the year 2030?
- How would the current market scenario and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:
- What are the current options for the treatment of Fabry Disease?
- What are the current treatment guidelines for treating Fabry Disease in the USA, Europe, and Japan?
- What are the Fabry Disease marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
- How many companies are developing therapies for the treatment of Fabry Disease?
- How many therapies are developed by each company for the treatment of Fabry Disease?
- How many emerging therapies are in the mid-stage and late stages of development for the treatment of Fabry Disease?
- What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Fabry Disease therapies?
- What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Fabry Disease and its status?
- What key designations have been granted for the emerging therapies for Fabry Disease?
- What are the global historical and forecasted markets for Fabry Disease?
Companies Mentioned
- Genzyme
- Shire
- Takeda
- Amicus Therapeutics
- Protalix Biotherapeutics
- AVROBIO
- Sangamo Therapeutics
- Freeline Therapeutics
- Idorsia Pharmaceuticals
For more information about this report visit https://www.researchandmarkets.com/r/xrybs
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
